Curis Inc. buy melinda
Start price
30.08.18
/
50%
€1.36
Target price
20.09.18
€1.89
Performance (%)
10.08%
End price
20.09.18
€1.50
Summary
This prediction ended on 20.09.18 with a price of €1.50. The prediction had a final performance of 10.08%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Curis Inc. | - | - | - | - |
| iShares Core DAX® | 0.060% | 1.215% | 18.128% | 70.406% |
| iShares Nasdaq 100 | -3.065% | -0.519% | 2.080% | 103.787% |
| iShares Nikkei 225® | -2.094% | -3.066% | 11.655% | 45.417% |
| iShares S&P 500 | -1.657% | -0.069% | 1.103% | 64.908% |
Comments by melinda for this prediction
In the thread Curis Inc. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 07/11 Publication de résultats
Curis, Inc. is a biotechnology company, which is focused on the development and commercialization of drug candidates for the treatment of human cancers.
Its pipeline includes CUDC-907, CA-170, and CA-327.
The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes.
The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints.
The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Nombre d'employés : 55 personnes.